Soligenix (SNGX) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual Meeting scheduled for June 20, 2025, with virtual participation available to shareholders.
Shareholders are encouraged to review proxy materials and vote by June 19, 2025, 11:59 PM ET.
Voting matters and shareholder proposals
Election of five directors to serve until the next Annual Meeting or until successors are elected and qualified.
Approval of the 2025 Equity Incentive Plan is proposed.
Advisory vote on executive compensation (say-on-pay) is included.
Ratification of Cherry Bekaert LLP as independent registered public accounting firm for 2025.
Approval to adjourn the meeting if necessary to solicit additional proxies.
Board of directors and corporate governance
Five nominees for director positions: Christopher J. Schaber, Gregg A. Lapointe, Diane L. Parks, Robert J. Rubin, and Jerome B. Zeldis.
Latest events from Soligenix
- Key votes include board elections, reverse stock split, and share authorization increase.SNGX
Proxy filing3 Aug 2026 - Proxy seeks approval for reverse split, share increase, and highlights governance and ESG focus.SNGX
Proxy filing3 Aug 2026 - Reverse split and share increase proposed to maintain Nasdaq listing and enable future growth.SNGX
Proxy filing23 Jul 2026 - Proxy seeks approval for reverse split, share increase, director elections, and executive pay.SNGX
Proxy filing21 Jul 2026 - Net loss narrowed, FLASH2 trial halted, focus shifts to pipeline amid funding risks.SNGX
Q1 202611 May 2026 - Late-stage pipeline addresses rare diseases and public health, backed by strong clinical data.SNGX
Corporate presentation8 Apr 2026 - Net loss rose to $11.1M in 2025, with liquidity concerns and new capital needed for continued operations.SNGX
Q4 202531 Mar 2026 - Late-stage rare disease therapies and vaccines show strong clinical and commercial promise.SNGX
Corporate presentation26 Mar 2026 - Late-stage pipeline addresses rare diseases and public health, backed by strong clinical data.SNGX
Corporate presentation20 Mar 2026 - Proxy seeks approval of director slate, new equity plan, executive pay, and auditor ratification.SNGX
Proxy Filing2 Dec 2025